Sam has over 30 years’ experience in the Life Sciences sector as a scientist, company CEO and investment manager. He is currently Managing Partner at IP Group plc., the FTSE 250 investor, where he oversees the group’s c.£500m Life Sciences portfolio. He is founding CEO and Chairman of Istesso Ltd, a Phase 2 drug-discovery company, and has served as founding investor, director and/or chairman of several leading UK private and public biotech businesses, including Diurnal Group plc, Pulmocide Ltd, Genomics plc and Akamis Ltd. Before founding Istesso, Sam was a top-ranked equity analyst in the City of London covering the biotechnology sector. Sam conducted his PhD and post-doctoral research in the Cambridge laboratory of Nobel Prize winner, Sir Gregory Winter, and has a degree in biology from Oxford.
